Peptide Based Cancer Therapeutics Market Forecast for Incremental CAGR Growth by 2022

Peptide based cancer therapeutics are yet to become widespread, but the initial low numbers certainly do not suggest any pessimism in the global market. With new developments in delivery, stability, modifications, and preclinical success, future growth potentials of such cancer therapeutics continue to intensify.  A slew of new peptides with positive preclinical results are entering into clinical trials that are focused on cancer treatment. Moreover, the application base of peptides is steadily expanding to other therapeutic areas as well. In the near future, the global peptide based cancer therapeutics market is likely to be influenced by the rising prevalence of cancer across the globe. WHO reveals that cancer is one of the leading causes of death worldwide, which accounted for more than 8 million deaths in 2015. Factor as such are expected to play an important role in boosting the popularity of peptide based cancer therapeutics further. In addition, various complications involved in conventional cancer therapeutics as well as the risk of sever side-effects are prompting medical professionals to utilise peptides in tumor and cancer treatment.

Request For Sample Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=179

Forecast Highlights Of Global Market For Peptide Based Cancer Therapeutics
Among regions, North America is expected to remain the most attractive market for peptide based cancer therapeutics during the forecast period. This is largely due to the existence of several prominent peptide based cancer therapeutic drug makers and an advanced healthcare infrastructure in the region. Over the next couple of years, the region’s market is projected to witness a healthy growth. Meanwhile, the market in Asia-Pacific excluding Japan (APEJ) is anticipated to register the fastest CAGR over 2022.
Based on drugs, demand for bortezomib is expected to remain relative higher as compared to other peptide based cancer therapeutic drugs.  Revenues from global sales of bortezomib drugs currently commands for nearly 40% market share.  Towards the end of 2022, more than US$ 4,700 Mn worth bortezomib drugs are estimated to be sold worldwide.

Hospital pharmacies are the largest distribution channel for peptide based cancer therapeutic drugs followed by retail pharmacies. Currently, hospital pharmacies account for close to 50% share of the global market in terms of revenue. The trend is likely to continue in 2017 and beyond.

North America To Lead The Global Peptide Based Cancer Therapeutics Market
In terms of revenues, North America is expected to dominate the global peptide based cancer therapeutics market in 2017 and beyond. The region’s potency in healthcare and a strong presence of various peptide based cancer therapeutic drug manufacturers is supporting the growth of the market in North America. During the forecast period, the market in the region is expected to surge at a robust CAGR.

On the basis of drugs, the bortezomib segment is expected to remain highly attractive throughout the assessment period. The segment currently accounts for around 40% revenue share of the global market. Between 2017 and 2022, the segment is expected to reflect a double-digit CAGR to reach a valuation is excess of US$ 4,725 Mn. It expected to grow at US$ 358.4 Mn annually over the course of the forecast period.

Browse Full Report with TOC @ https://www.factmr.com/report/179/peptide-based-cancer-therapeutics-market

Competition Tracking
Fact.MR’s report has also profiled key companies that are operating in the global peptide based cancer Therapeutic market, which include AstraZeneca PLC, Allergan plc, Pfizer Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Abbott, AbbVie Inc., and Valeant Pharmaceuticals International, Inc.

Check Discount @ https://www.factmr.com/connectus/sample?flag=D&rep_id=179

About Fact.MR       
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized “Healthcare market research reports”. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/

This release was published on openPR.